BACKGROUND

Primary biliary cholangitis (PBC) is a chronic and slowly progressing cholestatic disease, which causes damage to the small intrahepatic bile duct by immuno-regulation, and may lead to cholestasis, liver fibrosis, cirrhosis and, eventually, liver failure.

AIM

To explore the potential diagnosis and staging value of plasma S100 calcium binding protein A6 (S100A6) messenger ribonucleic acid (mRNA), LINC00312, LINC00472, and LINC01257 in primary biliary cholangitis.

METHODS

A total of 145 PBC patients and 110 healthy controls (HCs) were enrolled. Among them, 80 PBC patients and 60 HCs were used as the training set, and 65 PBC patients and 50 HCs were used as the validation set. The relative expression levels of plasma S100A6 mRNA, long noncoding ribonucleic acids LINC00312, LINC00472 and LINC01257 were analyzed using quantitative reverse transcription-polymerase chain reaction. The bile duct ligation (BDL) mouse model was used to simulate PBC. Then double immunofluorescence was conducted to verify the overexpression of S100A6 protein in intrahepatic bile duct cells of BDL mice. Human intrahepatic biliary epithelial cells were treated with glycochenodeoxycholate to simulate the cholestatic environment of intrahepatic biliary epithelial cells in PBC.

RESULTS

The expression of S100A6 protein in intrahepatic bile duct cells was up-regulated in the BDL mouse model compared with sham mice. The relative expression levels of plasma S100A6 mRNA, log10 LINC00472 and LINC01257 were up-regulated while LINC00312 was down-regulated in plasma of PBC patients compared with HCs (3.01±1.04 vs 2.09±0.87, P< 0.0001; 2.46±1.03 vs 1.77±0.84, P< 0.0001; 3.49±1.64 vs 2.37±0.96, P< 0.0001; 1.70±0.33 vs 2.07±0.53, P< 0.0001, respectively). The relative expression levels of S100A6 mRNA, LINC00472 and LINC01257 were up-regulated and LINC00312 was down-regulated in human intrahepatic biliary epithelial cells treated with glycochenodeoxycholate compared with control (2.97±0.43 vs 1.09±0.08, P= 0.0018; 2.70±0.26 vs 1.10±0.10, P= 0.0006; 2.23±0.21 vs 1.10±0.10, P= 0.0011; 1.20±0.04 vs 3.03±0.15, P< 0.0001, respectively). The mean expression of S100A6 in the advanced stage (III and IV) of PBC was up-regulated compared to that in HCs and the early stage (II)(3.38±0.71 vs 2.09±0.87, P< 0.0001; 3.38±0.71 vs 2.57±1.21, P= 0.0003, respectively); and in the early stage (II), it was higher than that in HCs (2.57±1.21 vs 2.09±0.87, P= 0.03). The mean expression of LINC00312 in the advanced stage was lower than that in the early stage and HCs (1.39±0.29 vs 1.56±0.33, P= 0.01; 1.39±0.29 vs 2.07±0.53, P< 0.0001, respectively); in addition, the mean expression of LINC00312 in the early stage was lower than that in HCs (1.56±0.33 vs 2.07±0.53, P< 0.0001). The mean expression of log10 LINC00472 in the advanced stage was higher than those in the early stage and HCs (2.99±0.87 vs 1.81±0.83, P< 0.0001; 2.99±0.87 vs 1.77±0.84, P< 0.0001, respectively). The mean expression of LINC01257 in both the early stage and advanced stage were up-regulated compared with HCs (3.88±1.55 vs 2.37±0.96, P< 0.0001; 3.57±1.79 vs 2.37±0.96, P< 0.0001, respectively). The areas under the curves (AUC) for S100A6, LINC00312, log10 LINC00472 and LINC01257 in PBC diagnosis were 0.759, 0.7292, 0.6942 and 0.7158, respectively. Furthermore, the AUC for these four genes in PBC staging were 0.666, 0.661, 0.839 and 0.5549, respectively. The expression levels of S100A6 mRNA, log10 LINC00472, and LINC01257 in plasma of PBC patients were decreased (2.35±1.02 vs 3.06±1.04, P= 0.0018; 1.99±0 …